Landscape Capital Management L.L.C. acquired a new position in shares of Envista Holdings Corporation (NYSE:NVST - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,610 shares of the company's stock, valued at approximately $1,017,000.
Other large investors have also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Envista during the 2nd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Envista by 16,711.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company's stock worth $31,000 after acquiring an additional 1,504 shares in the last quarter. Allworth Financial LP increased its stake in Envista by 75.4% in the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company's stock valued at $39,000 after acquiring an additional 776 shares during the last quarter. UMB Bank n.a. increased its stake in Envista by 46.1% in the fourth quarter. UMB Bank n.a. now owns 2,017 shares of the company's stock valued at $44,000 after acquiring an additional 636 shares during the last quarter. Finally, IFP Advisors Inc raised its position in Envista by 102.9% during the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company's stock valued at $46,000 after purchasing an additional 1,071 shares in the last quarter.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on NVST shares. Zacks Research upgraded Envista from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 7th. Wall Street Zen raised Envista from a "buy" rating to a "strong-buy" rating in a report on Saturday. Mizuho set a $29.00 price target on Envista in a report on Thursday, August 6th. Robert W. Baird set a $34.00 price objective on Envista in a research note on Thursday, August 6th. Finally, BMO Capital Markets assumed coverage on Envista in a research note on Wednesday, July 8th. They issued a "market perform" rating and a $27.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.31.
Read Our Latest Report on Envista
Envista Stock Performance
NYSE NVST opened at $27.21 on Monday. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of 46.91, a PEG ratio of 1.30 and a beta of 0.86. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47. Envista Holdings Corporation has a twelve month low of $18.77 and a twelve month high of $30.42. The stock has a fifty day simple moving average of $26.90 and a 200 day simple moving average of $26.30.
Envista (NYSE:NVST - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.34 by $0.07. Envista had a return on equity of 7.88% and a net margin of 3.33%.The firm had revenue of $730.50 million for the quarter, compared to the consensus estimate of $716.11 million. During the same period in the previous year, the business earned $0.26 EPS. The business's quarterly revenue was up 7.1% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. Sell-side analysts expect that Envista Holdings Corporation will post 1.53 EPS for the current year.
Envista Profile
(
Free Report)
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.